MRSA Drug Market To Reach $9 Billion By 2036 Amid Rising Infection Rates
-
The global methicillin-resistant Staphylococcus aureus (MRSA) drugs market is projected to reach USD 9 billion by 2036, growing at a CAGR of 5% between 2024-2036.
-
The market growth is driven by the rising incidence of MRSA infections worldwide, with a prevalence rate of over 16% as of 2023.
-
North America is estimated to account for over 40% market share during 2024-2036, owing to increasing awareness of hygiene and government support for MRSA treatment.
-
The lipopeptide drug class segment is expected to account for 39% market share by 2036, due to the emergence of new antibiotic therapies.
-
Key players in the MRSA drugs market include BD, Melinta Therapeutics, Dr. Reddy’s Laboratories, Cardinal Health, Pfizer Inc., and others.